Compare ST & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ST | TGTX |
|---|---|---|
| Founded | 1916 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.9B |
| IPO Year | 2009 | 2008 |
| Metric | ST | TGTX |
|---|---|---|
| Price | $38.62 | $34.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $40.27 | ★ $49.80 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | 0.21 | ★ 2.77 |
| Revenue | ★ $3,704,500,000.00 | $2,785,000.00 |
| Revenue This Year | $6.03 | $49.08 |
| Revenue Next Year | $4.15 | $26.69 |
| P/E Ratio | $184.19 | ★ $12.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.57 | $25.37 |
| 52 Week High | $39.91 | $46.48 |
| Indicator | ST | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 64.67 |
| Support Level | $33.15 | $33.58 |
| Resistance Level | $38.91 | $37.11 |
| Average True Range (ATR) | 1.26 | 1.08 |
| MACD | 0.41 | 0.09 |
| Stochastic Oscillator | 79.56 | 77.96 |
Sensata Technologies is a global supplier of sensors and electrical protection for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. It also sells electrical protection products, like contactors and relays. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.